Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories
Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.
More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio
In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.
Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 30,000+
ASCO 2013: Cetuximab superior to bevacizumab for advanced colorectal cancer
The German phase III clinical trial FIRE-3 reports that first-line cetuximab plus FOLFIRI chemotherapy (folinic acid, fluorouracil, irinotecan) offers a roughly four-month survival advantage for patients with metastatic colorectal cancer, compared wi...
The German phase III clinical trial FIRE-3 reports that first-line cetuximab plus FOLFIRI chemotherapy (folinic acid, fluorouracil, irinotecan) offers a roughly four-month survival advantage for patients with metastatic colorectal cancer, compared wi...
Zaltrap Approved for Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has approved Zaltrap® (ziv-aflibercept) for use in combination with the FOLFIRI chemotherapy regimen (folinic acid, fluorouracil, and ironotecan) to treat adults with metastatic colorectal cancer. Colorect...
Cetuximab superior to bevacizumab for advanced colorectal cancer
Dr Volker Heinemann presents data on the German phase III clinical trial FIRE-3 during a press conference at the 2013 ASCO Annual Meeting in Chicago. The trial reported that first-line cetuximab plus FOLFIRI chemotherapy (folinic acid, fluorouracil,...
Maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond disease progression has clinical benefits in patients with metastatic colorectal cancer. This approach is also being investigated in other tumour types, inc...
Cediranib no better than bevacizumab in advanced colorectal cancer
NEW YORK (Reuters Health) - In the first-line treatment of advanced colorectal cancer, the combination of cediranib and chemotherapy is comparable to bevacizumab plus chemotherapy in terms of progression-free and overall survival, a multinati...
[Comment] S-1 in colorectal cancer: a new standard of care?
Substantial advances have been made in palliative therapy for metastatic colorectal cancer in the past 15 years. These advances were driven by the introduction of various cytotoxic and biological agents into standard treatment algorithms for the dise...
Combo Treatment Effective in Elderly Patients with Metastatic Colorectal Cancer
Combination therapy with Avastin® (bevacizumab) and Xeloda® (capecitabine) may be an optimal first-line treatment for treatment-naïve older patients with metastatic colorectal cancer, according to the results of a study presented at the 2013 Gastr...
Bevacizumab doesn't prolong survival in stage II-III colon CA
(HealthDay)—For patients with stage 2 to 3 colon cancer, the addition of bevacizumab to modified fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) does not prolong disease-free or overall survival, according to a study published online Dec. 10 in...
Results from Amgen’s Neulasta plus bevacizumab Phase 3 trial on colorectal cancer
Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-adva...
Cetuximab Superior to Bevacizumab as First-Line Tx in CRC
Cetuximab added to FOLFIRI chemotherapy increased survival by about 4 months in patients with metastatic colorectal cancer, compared with bevacizumab. Medscape Medical News
FDA approves Zaltrap for metastatic colorectal cancer
The U.S. Food and Drug Administration today approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.
miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer
U.S. FDA approves Zaltrap for metastatic colorectal cancer
Aug 3 (Reuters) - The U.S. Food and Drug Administration said on Friday that it had approved Sanofi SA and Regeneron Pharmaceuticals Inc's Zaltrap for use in combination with a folinic acid, fluorouracil and irinotecan chemotherapy regimen to treat ad...
New Drug Approved for Metastatic Colorectal Cancer
The Food and Drug Administration approved ziv-aflibercept (Zaltrap) for use in combination with the FOLFIRI (leucovorin, fluorouracil, and irinotecan) chemotherapy regimen to treat some adults with colorectal cancer.
Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use
FDA approves use of Genentech’s bevacizumab for second-line treatment of metastatic colorectal cancer patients who have progressed on a first-line, Avastin-containing chemotherapeutic regimen.
Avastin Wins New Colorectal Ca Indication
(MedPage Today) -- The FDA has approved a new use of bevacizumab (Avastin) as part of second-line combination therapy for metastatic colorectal cancer, the drug's manufacturer announced.
Fujifilm JV plans bevacizumab biosimilar; Fujifilm Diosynth Bio alliance with Piramal for ADCs
Fujifilm Kyowa Kirin Biologics has that it will endeavor to develop a biosimilar version of bevacizumab, an anti-VEGF humanized monoclonal antibody which has impressive therapeutic effects for cancers such as colorectal cancer and non-small cell lung...
Sanofi-aventis receives FDA approval for Zaltrap to treat colorectal cancer
The U.S. Food and Drug Administration today approved Zaltrap (ziv-aflibercept) for use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer.
EORTC BOS 2 trial to test efficacy of adding bevacizumab to peri-operative FOLFOX 4 chemotherapy
Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherap...
Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model...
Bevacizumab Slows Progression Of Metastatic Breast Cancer But Has No Impact On Survival
The cancer drug bevacizumab (Avastin®) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bev...
(Rana Healthcare Solutions LLC) Certara, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services ha...
